Figure 2.

AntagomiR-122-5p improved the behavioral and cognitive impairment of RBI-model mice

(A) The concrete sequence and structure of antagomiR-122-5p and a schematic diagram of its combination with miR-122-5p. (B) General plan and timeline of the antagomiR-122-5p intervention and tests. The detailed phases and tests are listed in the Materials and methods (from days 0 to 52). (C and D) The total distance traveled (C) and exploratory rearing (D) behaviors of mice from different groups in the OFT. n = 11. (E) Immobility time in the TST. n = 11. (F and G) The escape latency (F) in the MWM test and the activity trajectory (G) of mice on the fifth day of the MWM test. (H) The distance traveled in the target quadrant (%), the time spent in the target quadrant, and the times the platform was crossed by mice on the sixth day. n = 11. (I and J) The time spent in the novel arm (I) and SAP (J) in the Y-maze. n = 11. (K) Recognition index in the NOR test. n = 11. Data are presented as means ± SEM, ns, not significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Four groups were established: control mice, RBI-model mice (Rad), RBI-model mice treated with antagomiR-122-5p (Rad + Ant-122), and RBI-model mice treated with antagomiR-122-5p negative control (Rad + Ant-NC).